Noxopharm Limited (ASX:NOX)

Noxopharm Limited (ASX:NOX)

Noxopharm Limited (ASX: NOX) is an Australian drug development company whose primary focus is on the development of drugs to make radiotherapy more effective. NOX66 is the first pipeline product, with later generation drug candidates under development in an R&D program and expected to enter the clinic in early-2019.


Alphastation assisted Noxopharm with investor materials including:

  • Completion of the prospectus for the company’s $6 million IPO on the ASX including content drafting, refinement, design and layout
  • Defined investor communication strategy and positioning from company launch
  • Liaison with company management, Board of Directors, legal advisor to the offers and broker to ensure project was delivered before deadline
  • Assisted in drafting and review of company announcements to the market
  • Design of the company’s annual reports
  • Design and editing of information memorandum for company’s subsidiary Nyrada, Inc – a US-based drug development company

Client since


Annual Reports, IPO Prospectus